ArticleBMC gastroenterology2012
Serological assessment of gastric mucosal atrophy in gastric cancer.
Article in BMC gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives.World journal of gastroenterology · 2018Pooled it
- Pooled it
- Short term micronutrient-antioxidant supplementation has no impact on a serological marker of gastric atrophy in Zambian adults: retrospective analysis of a randomised controlled trial.BMC gastroenterology · 2014Trial
- Gastric Mucosa Cancer Risk: The Operative Link on Gastritis Assessment Staging System.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Diagnostic Value of Serum Pepsinogen andGastroenterology research and practice · 2026Article
- Assessing Serum Pepsinogen andCancers · 2025Article
- A Proton Pump Inhibitor Independently Elevates Gastrin Levels as a Marker for Metachronous Gastric Cancer After Endoscopic Submucosal Dissection.Journal of clinical medicine · 2024Article
- Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers.International journal of molecular sciences · 2023Article
- Differential Expression of Tissular miRNA-155 in Pediatric Gastritis.Journal of clinical medicine · 2022Article
- Diagnostic performances of pepsinogens and gastrin-17 for atrophic gastritis and gastric cancer in Mongolian subjects.PloS one · 2022Article
- Machine learning: A non-invasive prediction method for gastric cancer based on a survey of lifestyle behaviors.Frontiers in artificial intelligence · 2022Article
- Serum pepsinogen levels in different regions of China and its influencing factors: a multicenter cross-sectional study.BMC gastroenterology · 2021Article
- Polymorphisms in Pepsinogen C and miRNA Genes Associate with High Serum Pepsinogen II in Gastric Cancer Patients.Microorganisms · 2021Article
- Diagnostic Value of Serum Pepsinogen Levels for Screening Gastric Cancer and Atrophic Gastritis in Asymptomatic Individuals: A Cross-Sectional Study.Frontiers in oncology · 2021Article
- LncRNA HCP5 : A Potential Biomarker for Diagnosing Gastric Cancer.Frontiers in oncology · 2021Article
- Type I and type IIWorld journal of gastroenterology · 2020Article
- Serum pepsinogens as a gastric cancer and gastritis biomarker in South and Southeast Asian populations.PloS one · 2020Article
- Endoscopic gastric mucosal atrophy as a predictor of colorectal polyps: a large scale case-control study.Journal of clinical biochemistry and nutrition · 2019Article
- Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer.Annals of translational medicine · 2019Article
- Nepalese Helicobacter pylori Genotypes Reflects a Geographical Diversity than a True Virulence FactorAsian Pacific journal of cancer prevention : APJCP · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-invasive tools for gastric cancer screening and diagnosis are lacking. Serological testing with the detection of pepsinogen 1 (PG1), pepsinogen 2 (PG2) and gastrin 17 (G17) offers the possibility to detect preneoplastic gastric mucosal conditions. Aim of this study was to assess the performance of these serological tests in the presence of gastric neoplasia.
methodsHistological and serological samples of 118 patients with gastric cancer have been assessed for tumor specific characteristics (Laurén type, localisation), degree of mucosal abnormalities (intestinal metaplasia, atrophy) and serological parameters (PG1, PG2, PG1/2-ratio, G17, H. pylori IgG, CagA status). Association of the general factors to the different serological values have been statistically analyzed.
resultsPatients with intestinal type gastric cancer had lower PG1 levels and a lower PG1/2-ratio compared to those with diffuse type cancer (p = 0.003). The serum levels of PG2 itself and G17 were not significantly altered. H. pylori infection in general had no influence on the levels of PG1, PG2 and G17 in the serum of gastric cancer patients. There was a trend towards lower PG1 levels in case of positive CagA-status (p = 0.058). The degree of both intestinal metaplasia and atrophy correlated inversely with serum levels for PG1 and the PG1/2-ratio (p < 0.01). Laurén-specific analysis revealed that this is only true for intestinal type tumors. Univariate ANOVA revealed atrophy and CagA-status as the only independent factors for low PG1 and a low PG1/2-ratio.
conclusionsGlandular atrophy and a positive CagA status are determinant factors for decreased pepsinogen 1 levels in the serum of patients with gastric cancer. The serological assessment of gastric atrophy by analysis of serum pepsinogen is only adequate for patients with intestinal type cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.